Mark Middleton

基本信息

Career Trajectory

Bio

RESEARCH SUMMARY
I’m interested in the development of new drugs to treat cancer, principally immunotherapies. To achieve this I work with scientists and drug companies to validate drug targets, optimise candidate molecules and design both pre-clinical testing programmes and early clinical trials, with the aim of bringing these trials to patients here in Oxford.

Research Interests

Papers共 509 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma

Reinhard Dummer,Shahneen Sandhu,Wilson H Miller,Marcus O Butler,Matthew H Taylor,Lucie Heinzerling,Christian U Blank, Eva Muñoz-Couselo,Howard A Burris,Michael A Postow,Bartosz Chmielowski,Mark R Middleton,Carola Berking,Jessica C Hassel, Anja Heike Gesierich,Cornelia Mauch, Joseph F Kleha,Anna Polli,Allison S Harney,Alessandra di Pietro,Paolo A Ascierto

Clinical cancer research an official journal of the American Association for Cancer Researchno. 11 (2025): 2097-2107

Cited0Views0WOSBibtex

A Phase Ia Study of the MEK1/2 Inhibitor PD-0325901 with the C-Met Inhibitor Crizotinib in Patients with Advanced Solid Cancers

Peter Gallagher,Christian Rolfo,Elena Elez,Julien Taieb, Jennifer Houlden, Linda Collins,Corran Roberts,Thierry André,Mark Lawler,Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd,Vlad Popovici,Alberto Bardelli, Robbie Carson,Hajrah Khawaja,Pierre Laurent-Puig,Manuel Salto-Tellez,Bryan T Hennessy, Tim S Maughan,Josep Tabernero,Richard Adams,Robert Jones,Marc Peeters,Mark R Middleton,Richard H Wilson,Sandra Van Schaeybroeck, MErCuRIC Trial Consortium

BJC reportsno. 1 (2025): 17-17

Cited0Views0WOSNATUREBibtex

Distinct Immune Cell Infiltration Patterns in Pancreatic Ductal Adenocarcinoma (PDAC) Exhibit Divergent Immune Cell Selection and Immunosuppressive Mechanisms

Shivan Sivakumar,Ashwin Jainarayanan,Edward Arbe-Barnes,Piyush Kumar Sharma,Maire Ni Leathlobhair, Sakina Amin,David J. Reiss,Lara Heij,Samarth Hegde,Assaf Magen, Felicia Tucci,Bo Sun, Shihong Wu,Nithishwer Mouroug Anand,Hubert Slawinski,Santiago Revale,Isar Nassiri, Jonathon Webber, Gerard D. Hoeltzel,Adam E. Frampton,Georg Wiltberger,Ulf Neumann,Philip Charlton,Laura Spiers,Tim Elliott,Maria Wang,Suzana Couto,Thomas Lila, Pallavur V. Sivakumar,Alexander V. Ratushny,Mark R. Middleton, Dimitra Peppa,Benjamin Fairfax,Miriam Merad, Michael L. Dustin,Enas Abu-Shah,Rachael Bashford-Rogers

Nature Communications（2025）

Cited0Views0WOSNATUREBibtex

Peripheral Monocyte Transcriptomics Associated with Immune Checkpoint Blockade Outcomes in Metastatic Melanoma

Rosalin A Cooper,Chelsea A Taylor,Robert A Watson,Orion Tong,Isar Nassiri,Piyush Kumar Sharma,Martin Little,Weiyu Ye,Surya Koturan,Sara Danielli,Mark Middleton,Benjamin P Fairfax

crossref（2024）

Cited0Views0Bibtex

A T-cell Signature in Circulating Cell-Free DNA at Time of Diagnosis Predicts Response to Checkpoint Inhibition

Phil Xie, Zohar Etzioni,Chun-Xiao Song,Richard P. Owen,Mark R. Middleton,Xin Lu,Benjamin Schuster-Boeckler

CLINICAL CANCER RESEARCHno. 21 (2024)

Cited0Views0Bibtex

Validity and Timeliness of Cancer Diagnosis Data Collected During a Prospective Cohort Study and Reported by the English and Welsh Cancer Registries: a Retrospective, Comparative Analysis

Ashley Jackson,Pradeep S. Virdee,Sharon Tonner,Jason L. Oke,Rafael Perera, Kaveh Riahi,Ying Luan,Sara Hiom,Harpal Kumar, Harit Nandani,Kathryn N. Kurtzman,Dyfed Huws, Dawn Allan,Stephanie Smits,Sean McPhail,Eileen E. Parkes,F. D. Richard Hobbs,Mark R. Middleton,Brian Nicholson

LANCET ONCOLOGYno. 11 (2024): 1476-1486

Cited0Views0WOSBibtex

High Tumor Monocyte Content Predicts Long-Term Survival for Patients with Operable Oesophageal Cancer Treated with Neoadjuvant Immunochemotherapy in the LUD2015-005 Trial

Hannah S. Fuchs, Sabrina A. James,Thomas M. Carroll,Phil F. Xie,Joseph A. Chadwick, Duncan Parkes,Simon R. Lord,Lucinda Griffiths,Tim Underwood,Ioannis Karydis, Russell T. Petty,Benjamin Schuster-Bockler,Richard P. Owen,Mark R. Middleton,Xin Lu

CANCER RESEARCHno. 7 (2024)

Cited0Views0Bibtex

694 Phase 1 Safety and Efficacy of Brenetafusp, a PRAME × CD3 ImmTAC Bispecific, in Post-Checkpoint Cutaneous Melanoma (CM)

Diwakar Davar,Anja Williams,Juanita Lopez,Daniel Olson,Takami Sato,Heather Shaw,Claire F Friedman,Fiona Thistlethwaite,Mark Middleton,Celeste Lebbe, Vincent T Ma, Benjamin Izar, Peter Lau, Oliver Bechter, Peter Kirk, Yuan,Shannon Marshall,Omid Hamid

Regular and Young Investigator Award Abstracts (2024)

Cited0Views0Bibtex

Binimetinib in Combination with Nivolumab or Nivolumab and Ipilimumab in Patients with Previously Treated Microsatellite-Stable Metastatic Colorectal Cancer with RAS Mutations in an Open-Label Phase 1b/2 Study

Elena Elez,Antonio Cubillo,Pilar Garcia Alfonso,Mark R. Middleton,Ian Chau, Baha Alkuzweny,Ann Alcasid,Xiaosong Zhang,Eric Van Cutsem

BMC Cancerno. 1 (2024): 1-10

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 509 篇Author StatisticsCo-AuthorSimilar Experts